关键信息
-
基因名
BIRC4
- 应用
-
别名
AP 13; API3; Apoptosis Inhibitor 3; Baculoviral IAP repeat containing 4; Baculoviral IAP Repeat Containing Protein 4
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P98170
-
表达区间
1-497aa
-
氨基酸序列
MTFNSFEGSK TCVPADINKE EEFVEEFNRL KTFANFPSGS PVSASTLARA GFLYTGEGDT VRCFSCHAAV DRWQYGDSAV GRHRKVSPNC RFINGFYLEN SATQSTNSGI QNGQYKVENY LGSRDHFALD RPSETHADYL LRTGQVVDIS DTIYPRNPAM YSEEARLKSF QNWPDYAHLT PRELASAGLY YTGIGDQVQC FCCGGKLKNW EPCDRAWSEH RRHFPNCFFV LGRNLNIRSE SDAVSSDRNF PNSTNLPRNP SMADYEARIF TFGTWIYSVN KEQLARAGFY ALGEGDKVKC FHCGGGLTDW KPSEDPWEQH AKWYPGCKYL LEQKGQEYIN NIHLTHSLEE CLVRTTEKTP SLTRRIDDTI FQNPMVQEAI RMGFSFKDIK KIMEEKIQIS GSNYKSLEVL VADLVNAQKD SMQDESSQTS LQKEISTEEQ LRRLQEEKLC KICMDRNIAI VFVPCGHLVT CKQCAEAVDK CPMCYTVITF KQKIFMS
-
分子量
56 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
BIRC4, also known as Baculoviral IAP Repeat Containing 4, is a member of the inhibitor of apoptosis protein (IAP) family, which plays a crucial role in regulating apoptosis and cell survival. It is characterized by the presence of several baculoviral IAP repeats that mediate interactions with various apoptotic proteins. The primary function of BIRC4 is to inhibit caspases, the key enzymes responsible for the execution phase of apoptosis, thereby promoting cell survival in various physiological and pathological contexts. Research has shown that BIRC4 is often overexpressed in many cancers, contributing to tumor progression and resistance to chemotherapy, making it a significant target for cancer therapies. Understanding the structure and function of BIRC4 is essential for developing novel therapeutic strategies aimed at inducing apoptosis in cancer cells. The use of recombinant proteins in research facilitates the study of BIRC4's biological functions and interactions in greater detail. By expressing BIRC4 as a recombinant protein, scientists can investigate its role in cellular pathways, its structural properties, and its potential as a drug target. Recent advancements in technologies such as CRISPR/Cas9 have further enhanced the capability to modulate BIRC4 expression, allowing for the exploration of its functions in vivo and in vitro. Overall, the ongoing research into BIRC4 and its recombinant protein offers exciting prospects for improving cancer treatment outcomes and understanding the complex mechanisms of cellular survival and death.
